natgillin/translations-raw huggingface dataset:
Use according to claim 46, wherein said S1P1 receptor-associated disorder is rheumatoid arthritis. 
Uporaba prema zahtjevu 46, naznačena time, da navedeni poremećaj povezan sa S1P1-receptorom je reumatoidni artritis.
Use according to claim 46, wherein said S1P1 receptor-associated disorder is multiple sclerosis. 
Uporaba prema zahtjevu 46, naznačena time, da navedeni poremećaj povezan sa S1P1-receptorom je multipla skleroza.
Use according to claim 46, wherein said S1P1 receptor-associated disorder is inflammatory bowel disease. 
Uporaba prema zahtjevu 46, naznačena time, da navedeni poremećaj povezan sa S1P1-receptorom je upalna bolest crijeva.
Use according to claim 46, wherein said S1P1 receptor-associated disorder is ulcerative colitis. 
Uporaba prema zahtjevu 46, naznačena time, da navedeni poremećaj povezan sa S1P1-receptorom je ulcerativni kolitis.
Apparatus as in claim 6 or 7, characterized in that said distance (H) is at least equal to double the distance between said at least two metal products (11). 
Uređaj prema zahtjevu 6 ili 7, naznačen time da je navedena udaljenost (H) barem jednaka dvostrukoj udaljenosti između navedena barem dva metalna proizvoda (11).
A biodegradable microsphere having a diameter of 10-2000 µm comprising cross-linked hydrolysed starch onto which at least one type of ligand which is selected from the group consisting of amino acids and nitrogen containing organic acids has been coupled via a carboxylic ester bond, wherein said ligand is an endogenous, positively charged molecule with a molecular mass of less than 1000 Da comprising at least one additional carboxylic acid function and/or at least one amine function, and wherein on average 0.05-1.5 ligands have been coupled to each glucose moiety in the hydrolysed starch. 
Biorazgradive mikrosfere koje imaju promjer od 10-2000 µm sadrže umreženi hidrolizirani škrob na koji je karboksilnom esterskom vezom vezana najmanje jedna vrsta liganda odabranog iz grupe koja se sastoji od aminokiselina i organskih kiselina koje sadrže dušik, pri čemu je navedeni ligand endogena, pozitivno nabijena molekula s molekulskom masom manjom od 1000 Da koja sadrži najmanje jednu dodatnu funkcionalnu karboksilnu kiselinu i/ili najmanje jednu funkcionalnu amino skupinu, i pri čemu je prosječno 0.05-1.5 liganda povezano sa svakom jedinicom glukoze u hidroliziranom škrobu.
A microsphere according to claim 1, wherein the ligand is an amino acid selected from the group consisting of arginine, histidine, lysine, glycine, proline, alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, serine, aspargine, glutamine, threonine, glutamic acid and aspartic acid; or a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine and dimethylglycine. 
Mikrosfera u skladu s patentnim zahtjevom 1, pri čemu je ligand aminokiselina odabrana iz grupe koja se sastoji od arginina, histidina, lizina, glicina, prolina, alanina, izoleucina, leucina, fenilalanina, triptofana, tirozina, valina, serina, asparagina, glutamina, treonina, glutaminske kiseline i aspartatne kiseline; ili organska kiselina koja sadrži dušik odabrana iz grupe koja se sastoji od betaina, karnitina, kreatina, metilglicina i dimetilglicina.
A microsphere according to claim 1 or 2, wherein the ligand has a physiologically active counter ion. 
Mikrosfere u skladu s patentnim zahtjevom 1 ili 2, pri čemu ligand ima fiziološki aktivni suprotni ion.
The controlled evacuation ostomy appliance (10) according to claim 3, wherein the foam (38) has a generally non-planar surface on a face that faces towards or away from the membrane (34), the non-planar surface providing local variation in the pressure exerted by the foam on the membrane (34). 
Kontrolirani uređaj za ostomijsko pražnjenje (10) prema zahtjevu 3, naznačen time da pjena (38) ima općenito ne-planarnu površinu lica koje je okrenuto prema ili od membrane (34), ne-planarna površina osigurava lokalno odstupanja pri porastu pritiska pjene na membranu (34).
The controlled evacuation ostomy appliance (10) according to claim 7, wherein at least one port (32) defines a fluid flow characteristic that is different in an inlet direction than in an outlet direction, and wherein the fluid flow characteristic is at least one selected from: 
Kontrolirani uređaj za ostomijsko pražnjenje (10) prema zahtjevu 7, naznačen time da najmanje jedan otvor (32) definira karakteristike toka tekućine koji se razlikuje u jednom ulaznom smjeru i jednom izlaznom smjeru, pri čemu je karakteristika toka tekućine barem jedno odabrano iz:
permits fluid to enter the chamber (36, 102) more easily than permitting fluid to leave the chamber (36, 102); 
dozvoljava da tekućina uđe u komoru (36, 102) lakše nego što dozvoljava da tekućina izađe iz komore (36, 102);
is a valve (60a, 65, 69, 72, 85) opening at a first pressure differential for inlet of fluid into the chamber (36, 102), and valve (60b, 65, 69, 72, 85) opening at a second pressure differential for exhaust of fluid from the chamber (36, 102), the magnitude of first pressure differential being different from the magnitude of the second pressure differential. 
ventil (60a, 65, 69, 72, 85) je koji se otvara pri prvoj razlici tlakova na ulazu tekućine u komoru (36, 102), i ventil (60b, 65, 69, 72, 85) je koji se otvara pri drugoj razlici tlaka za ispuštanje tekućine iz komore (36, 102), veličina prve razlike tlaka se razlikuje od veličine druge razlike tlaka.
a check valve (60a) configured to obstruct flow in one direction and to permit flow in an opposite direction; 
nepovratni ventil (60a), konfiguriran da ometa protok u jednom smjeru, a da se omogući protok u suprotnom smjeru;
a flow resistance for restricting the flow through the port (32, 32a, 32b); a valve (60a, 60b, 65, 69, 72, 85) in combination with the flow resistance (v); and 
zapreku protoka za ograničavanje protoka kroz otvor (32, 32a, 32b); (vi) ventil (60a, 60b, 65, 69, 72, 85) u kombinaciji sa zaprekom protoka (v); i
a fluid flow control device that (60) is configured to open permanently when a pressure threshold is reached. 
uređaj za kontrolu protoka (60) konfiguriran tako da je stalno otvoren kada je postignut prag tlaka.
The controlled evacuation ostomy appliance (10) according to claim 1, further comprising a second chamber (102) coupled to the at least one port (32, 32a, 32b). 
Kontrolirani uređaj za ostomijsko pražnjenje (10) prema zahtjevu 1, naznačen time da nadalje obuhvaća drugu komoru (102) vezanu za najmanje jedan otvor (32, 32a, 32b).
an entropy decoder (210) configured to restore quantized residual coefficients and intra prediction information; 
entropijski dekoder (210) konfiguriran za vraćanje kvantiziranih rezidualnih koeficijenata i intrapredikcijskih informacija;
a reference pixel generator (240) configured to generate reference pixels corresponding to unavailable reference pixels and to adaptively filter the reference pixels according to the intra prediction mode; 
generator referentnih piksela (240) konfiguriran za generiranje referentnih piksela koji odgovaraju nedostupnim referentnim pikselima i za adaptivno filtriranje referentnih piksela u skladu s intrapredikcijskim režimom;
The antibody for use of claim 1, where: the amount of anti-sclerostin antibody administered is from about 1 mg/kg to about 5 mg/kg; 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da je količina protutijela protiv sklerostina koja se primjenjuje od 1 mg/kg do 3 mg/kg.
the amount of anti-sclerostin antibody administered is about 2 mg/kg or about 3 mg/kg; the antibody is administered to the subject once every two weeks; or 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je količina protutijela protiv sklerostina koja se primjenjuje oko 3 mg/kg.
An anti-sclerostin antibody for use in a method for treating a bone-related disorder in a human, the method comprising administering to a human an anti-sclerostin antibody at a dose of from 70 to 450 mg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da postupak obuhvaća davanje protutijela protiv sklerostina čovjeku u dozi od 70 do 450 mg.
The antibody for use of claim 6, where the method comprises administering a dose of about 140 mg or a dose of about 210 mg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da postupak obuhvaća davanja doze od oko 140 mg.
The method as claimed in claim 1, wherein the CBD is in a pure or isolated form. 
Kombinacija za upotrebu prema patentnom zahtevu 1, pri čemu je fitokanabinoidni kanabidiol (CBD) u čistom ili izoliranom obliku.
The TGFß antagonist of claim 1, wherein said TGFß antagonist is an agent that blocks the binding of a TGFß protein to its receptor. 
Komplet prema zahtjevu 9, naznačen time da navedeni TGFß antagonist je sredstvo koje blokira vezanje TGFß proteina na njegov receptor.
A beverage prepared from a barley plant, or a part thereof, wherein said beverage contains a level of dimethyl sulfide (DMS) below 20 ppb and a level of S-methyl-I-methionine (SMM) of less than 20 ppb, and wherein said barley plant, or part thereof, carries a mutation in the gene encoding methionine S-methyltransferase (MMT), causing a total loss of functional MMT. 
Piće pipravljeno od biljke ječma, ili njegova dijela, pri čemu piće sadrži razinu dimetil sulfida (DMS) nižu od 20 ppb i razinu S-metil-I-metionina (SMM) nižu od 20 ppb, i pri čemu navedena biljka ječma, ili njezin dio, nosi mutaciju genetskog koda metionin S-metiltransferaze (MMT), koja uzrokuje potpuni gubitak funkcionalnog MMT.
A barley plant, or part thereof, wherein the barley plant carries a mutation in the gene encoding methionine-S-methyltransferase (MMT) that causes a total loss of MMT function. 
Biljka ječma, ili njezin dio, pri čemu biljka nosi mutaciju genetskog koda metionin-smetiltransferaze (MMT) koja uzrokuje potpun gubitak MMT funkcije.
The barley plant, or part thereof, according to claim 6, wherein the mutation is within a splice site of the gene encoding MMT. 
Biljka ječma, ili njezin dio, sukladno zahtjevu 6, pri čemu je mutacija unutar mjesta spoja genetskog koda MMT.
A malt composition comprising a processed barley plant, or part thereof, wherein said barley plant is the barley plant according to any of claims 6 to 9. 
Spoj slada koji sadrži prerađeni ječam, ili njegov dio, pri čemu je navedeni ječam biljka ječma sukladno bilo kojem od zahtjeva 6 do 9.
A wort composition prepared using the barley plant, or part thereof, according to any of claims 6 to 9, or using a malt composition prepared from said barley plant or part thereof, or mixtures thereof, wherein the wort composition comprises less than 20 ppb SMM. 
Sastav sladovine pripravljem pomoću ječma, ili njegovog dijela, sukladno bilo kojem od zahtjeva 6 do 9, ili uporabom spoja pripravljenog od navedenog ječma ili njegovog dijela, ili njihovih mješavina, pri čemu spoj sladovine sadrži manje od 20 ppb SMM.
A method of producing a beverage containing less than 20 ppb DMS and less than 20 ppb SMM, said method comprising the steps of: 
Postupak proizvodnje pića koje sadrži manje od 20 ppb DMS i manje od 20 ppb SMM, navedeni postupak sadrži korake:
processing the composition of (i) into a beverage; 
prerada spoja (i) u piće;
A method of producing a malt composition comprising at the most 200 ppb free DMS, said method comprising the steps of: 
Postupak proizvodnje sastava slada na najviše 200 ppb slobodnog DMS, navedena metoda sadrži korake:
providing kernels of a barley plant according to any one of claims 6 to 9; 
pružanje zrnja ječma sukladno bilo kojem od zahtjeva 6 do 9;
thereby producing a malt composition comprising at the most 200 ppb free DMS. 
proizvodeći time spoj slada koji sadrži najviše 200 ppb slobodnog DMS.
The barley plant or part thereof according to any one of claims 6 to 9, wherein the barley plant carries a mutation in the gene encoding lipoxygenase 1, causing a total loss of lipoxygenase 1 activity. 
Biljka ječma ili njezin dio sukladno bilo kojem od zahtjeva 6 to 9, pri čemu biljka ječma nosi mutaciju genetskog koda lipoksigenaze 1, uzrokujući poptpun gubitak aktivnosti lipogenaze 1.
The malt composition according to any one of claims 11 to 12, wherein the malt composition is prepared from the barley plant, or part thereof, according to claim 16. 
Spoj slada sukladno bilo kojem od zahtjeva 11 do 12, pri čemu je slad pripravljen od ječma, ili njegovog dijela, sukladno zahtjevu 16.
The wort composition according to claim 13, wherein the wort composition is prepared from the barley plant, or part thereof, according to claim 16. 
Spoj sladovine sukladno zahtjevu 13, pri čemu je sladovina pripravljena od ječma, ili njegovog dijela, sukladno zahtjevu 16.
The beverage according to any one of claims 1 to 5, wherein the beverage is prepared from the barley plant or part thereof, according to claim 16. 
Piće sukladno bilo kojem od zahtjeva 1do 5, pri čemu je piće pripravljeno od ječma, ili njegovog dijela, sukladno zahtjevu 16.
A peptide consisting of a sequence that is selected from the group of SEQ ID No. 
Peptid koji se sastoji od sekvence koja je odabrana iz grupe SEQ ID br.
The peptide according to Claim 1 or 2, wherein said peptide is part of a fusion protein. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni peptid dio fuzijskog proteina.
A host cell comprising the nucleic acid or the expression vector according to claim 5, wherein said host cell preferably is an antigen presenting cell, for example a dendritic cell, and wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, pri čemu je stanica domaćin po mogućnosti stanica koja prezentira antigen, primjerice dendritična stanica, i pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 4. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I ili II s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4.
An activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 9, that selectively recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 10, koji selektivno prepoznaje stanicu koja abnormalno eksprimira polipeptid koji se sastoji od sekvence aminokiselina navedene u patentnom zahtjevu 1.
A peptide according to any one of claims 1 to 4, the cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10 for use in the treatment of cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 10 za upotrebu u liječenju karcinoma.
A polymorphic or solvated solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1 H-pyrazol-3-yl]oxy]ethyl]morpholine, which is selected from the group consisting of: 
Polimorfni ili solvatirani čvrsti oblik hidrokloridne soli 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oksi]etil]morfolina, naznačen time što se bira iz skupine koju čine:
The process according to claim 5, wherein the mixture is performed at a temperature ranging from room temperature to 90 °C. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se miješanje provodi na rasponu temperatura od sobne temperature do 90 °C.
The process according to claim 5, wherein the mixture is performed by a liquid-liquid diffusion or a gas-liquid diffusion. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se miješanje provodi tekućinsko-tekućinskom difuzijom ili plinsko-tekućinskom difuzijom.
A process for the preparation of the polymorphic phase I form as defined in claim 1, wherein a suspension comprising 4-[2-[[5-methyl-1-(2-naphthalenyl)-1 H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride is prepared. 
Postupak dobivanja polimorfne faze I oblika u skladu s patentnim zahtjevom 1, naznačen time što se dobiva suspenzija koja sadrži 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oksi]etil]morfolin-hidroklorid.
The process according to claim 9, wherein the suspension is maintained at a temperature ranging from room temperature to 80 °C. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se suspenziju održava u rasponu temperatura od sobne temperature do 80 °C.
Pipe clamp as claimed in claim 2, wherein the divided closure further comprises locking elements (49) for locking the tongues (47) in the cavities (48). 
Stezaljka za cijev prema Zahtjevu 2, gdje podijeljeni element za zatvaranje dalje sadrži elemente (49) za zabravljivanje radi zabravljivanja jezičaka (47) u šupljinama (48).
Pipe clamp as claimed in claim 1, wherein the divided closure comprises a snap connection which is provided with at least one protrusion (37) and at least one closing cavity (38) co-acting with the protrusion. 
Stezaljka za cijev prema Zahtjevu 1, gdje podijeljeni element za zatvaranje sadrži spojnicu kod koje se veza ostvaruje pritiskom a koja ima najmanje jedan istureni dio (37) i najmanje jednu zatvarajuću šupljinu (38) koja djeluje zajedno sa isturenim dijelom.
Pipe clamp as claimed in claim 6, wherein a first end of the respective clamping element (35) is coupled to the hinge (13) via a coupling (33). 
Stezaljka za cijev prema Zahtjevu 6, gdje je prvi završetak navedenog steznog elementa (35) spregnut sa šarkom (13) pomoću spojnice (33).
Pipe clamp as claimed in claim 8, wherein in a first position of the coupling (33) the clamping elements (35) partially fill the further recess (34) for the purpose of clamping a pipe with a first diameter to a wire of the mesh reinforcement. 
Stezaljka za cijev prema Zahtjevu 8, gdje u prvom položaju spojnice (33) stezni elementi (35) djelomično ispunjavaju dodatno ulegnuće (34) radi stezanja cijevi prvog dijametra sa žicom armaturne mreže.
Pipe clamp as claimed in claims 7-10, wherein the coupling (33) is integrated in the hinge (13). 
Stezaljka za cijev prema Zahtjevima 7 do 10, gdje je spojnica (33) integrirana u šarku (13).
alpha lipoic acid, for use in the treatment of infertility. 
alfa lipoičnu kiselinu, za uporabu u liječenju neplodnosti.
The composition for use in accordance with claim 1, wherein said alpha lipoic acid is present as a 50/50 racemic R-(+)-alpha lipoic acid/S-(-)-alpha lipoic acid mixture. 
Pripravak za uporabu sukladno zahtjevu 1, pri čemu je alfa lipoična kiselina prisutna kao 50/50 racemična mješavina R-(+)-alfa lipoična kiselina/S-(-)-alfa lipoična kiselina.
The composition for use in accordance with claim 1 or 2, wherein said acid alpha lipoic is present in microencapsulated or coated form. 
Pripravak za uporabu sukladno zahtjevu 1 ili 2, pri čemu je alfa lipoična kiselina prisutna u mikrokapsuliranom ili prevučenom obliku.
The composition for use in accordance with any one of the preceding claims, wherein said composition consists of: 
Pripravak za uporabu sukladno bilo kojem od prethodnih zahtjeva, pri čemu se navedeni pripravak sastoji od:
The composition for use in accordance with any one of the preceding claims, wherein said composition is in solid form for oral administration, preferably tablets or granules for sachets or hard capsules. 
Pripravak za uporabu sukladno bilo kojem od prethodnih zahtjeva, pri čemu je navedeni pripravak u čvrstom obliku radi oralne primjene, poželjno tabletama ili granulama za vrećice ili čvrstima kapsulama.
The utility vault lid according to claim 3 in which the bottom wall of the receptacle includes drainage holes. 
Kanalski otvor prema zahtjevu 3 naznačen time da donja stjenka posude sadrži otvore za drenažu.
The utility vault lid according to claim 3 wherein the peripheral rim of the liner is positioned in a recessed region on the upper surface of the lid. 
Kanalski otvor prema zahtjevu 3 naznačen time da je periferni rub brtve smješten u udubljenom području na gornjoj površini poklopca.
The utility vault lid according to claim 3 including a removable cap in an upper portion of the liner. 
Kanalski otvor prema zahtjevu 3 naznačen time da sadrži odvojivu kapicu u gornjem dijelu brtve.
each R' is independently -R, or two R' groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
svaki R’ je nezavisno -R, ili su dvije R’ skupine na istom dušiku uzete zajedno sa svojim spojenim atomima da formiraju po izboru supstituirani 5-8-eročlani zasićeni, djelomično nezasićeni, ili aromatski prsten s 1-4 heteroatoma nezavisno odabrana između dušika, kisika ili sumpora;
each Rx on a nitrogen is independently hydrogen or C1-4 alkyl; and each R' is independently hydrogen or C1-4 alkyl, or two R' on the same nitrogen are taken together with the intervening nitrogen to form a 4-7 membered heterocylic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 
svaki Rx na dušiku je nezavisno vodik ili C1-4 alkil; i svaki R’ je nezavisno vodik ili C1-4 alkil, ili su dva R’ na istom dušiku uzeta zajedno sa spojenim dušikom da formiraju 4-7-eročlani heterociklički prsten s 1-2 heteroatoma nezavisno odabrana između dušika, kisika ili sumpora.
The composition according to any one of claims 1 to 11, wherein the alpha lipoic is present in microencapsulated or coated form. 
Pripravak za uporabu sukladno zahtjevu 1 ili 2, pri čemu je alfa lipoična kiselina prisutna u mikrokapsuliranom ili prevučenom obliku.
or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 
ili farmaceutski prihvatljiva sol, ester, stereoizomer, smjesa stereoizomera ili tautomer tog spoja.
A compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof for use in therapy; preferably for use in treating a disease state in a human that is alleviable by treatment with an agent capable of reducing late sodium current preferably 
Spoj u skladu sa bilo kojim od patentnih zahtjeva od 1 do 12 ili njegova farmaceutski prihvatljiva sol za upotrebu u terapiji; poželjno za upotrebu u liječenju stanja bolesti kod čovjeka koje je olakšano liječenjem agensom koji je sposoban da reducira kasnu struju natrijuma.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I ili II s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4.